Drug Profile
PF 6473871
Alternative Names: EXC-001; PF-06473871; PF-6473871Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Excaliard Pharmaceuticals; Isis Pharmaceuticals
- Developer Pfizer
- Class Antisense oligonucleotides
- Mechanism of Action Connective tissue growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Scars
Most Recent Events
- 28 Jul 2015 Discontinued - Phase-II for Scars in USA, Germany, Netherlands, Spain, Hungary (Intradermal)
- 08 Sep 2014 Pfizer completes enrolment in its phase II trial for Scars in USA, Germany, Hungary, Netherlands & Spain (NCT01730339)
- 05 Sep 2014 Pfizer plans a phase II extension trial for Scars in USA (NCT02205476)